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Background 
Over a quarter of Indigenous Australian adults have some form of cardiovascular disease 
(CVD) 1. In Australia, clinical guidelines for primary prevention of CVD recommend the 1991 
Framingham CVD model 2 as an important component of guidelines used to identify those at 
high risk of developing CVD over a 5-year period 3. The development of CVD risk prediction 
models using Framingham study data dates back to the late 1960s 4, 5. The most widely 
used model was developed by Anderson and colleagues to predict the risk of developing 
CVD and its component diseases (coronary heart disease (CHD), myocardial infarction, and 
stroke) for people aged 30-75 years 2. In 2008 an updated sex-specific Framingham model 
was published to predict 10-year CVD risks 6. 
The Framingham CVD models have been validated and recalibrated in various countries 
and ethnicities 7-9, as well as in the Australian general population 10, 11. However, it has not 
been validated or recalibrated for an Australian Indigenous population. One previous study 
(2005) compared the predicted and observed CHD rates in an Australian Aboriginal remote 
community sample and found that the 1991 Framingham model substantially 
underestimated CHD rates across all age groups and both sexes 12. In the current Australian 
CVD management guidelines, people with the following characteristics are automatically put 
into the high risk category, 
 diabetes and aged over 60 years 
 diabetes with microalbuminuria 
 eGFR<45mL/min/1.73m2 
 familial hypercholesterolemia 
 high blood pressure and serum total cholesterol >7.5mmol/L, and 
 any Aboriginal or Torres Strait Islander over the age of 74 years 3. 
However, the developers of these guidelines acknowledge that there is little empirical 
evidence supporting this classification system (a combination of level D weak evidence plus 
a consensus-based recommendation) 3. Further, for Aboriginal and Torres Strait Islander 
adults aged between 35 and 74 years who are not in this clinically determined high risk 
category, the guidelines recommend the use of the 1991 Framingham CVD model to 
estimate 5-year absolute CVD risks while acknowledging that it might result in an 
underestimation of these risks 3. 
In this study, we validated both the 1991 and 2008 Framingham CVD models using a cohort 
of Aboriginal and Torres Strait Islander adults drawn from remote Indigenous communities in 
Far North Queensland. Recalibration was also conducted to help generate more accurate 
CVD risk predictions for this population. Finally, we developed a CVD risk chart that could 
help improve the assessment and management of CVD in the Australian Indigenous 
population, particularly those in remote regions of Australia. 
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Methods 
PARTICIPANTS  
The source population for the present study was obtained from the Well Person’s Health 
Check (WPHC), which was conducted between 1998 and 2000 and consisted of 3,508 
people in 26 remote Indigenous communities in Far North Queensland 13. The study was 
approved by the Cairns Institutional Health Ethics Committee with support from Apunipima 
Cape York Health Council (HREC/141QCH/121-936). Participation in the WPHC study was 
open to all people residing in these communities and utilised a broad range of recruitment 
strategies including printed media and local radio, as well as through health services and 
community groups 13. Information collected in the WPHC survey can be found in the 
Appendices. 
Baseline data of the participants were linked to hospitalisation and death records in the 
Queensland Hospital Admitted Patient Data Collection dataset from the initial screening date 
to the end of 2014, using linkage software applying deterministic and probabilistic 
methodologies, as well as manual clerical reviews where required. For our study, we 
included 1,684 (98.8%) people aged between 30 and 74 years who have a unique link to 
their hospitalisation and death records. We excluded people with previous CVD events 
(n=101) or whose baseline characteristics were missing (n=135). 
Baseline risk factors including systolic blood pressure, total cholesterol level, high-density 
lipoprotein (HDL) cholesterol level, fasting glucose level and smoking status were collected 
from the WPHC screening data. Details of the methods used to collect these indicators have 
been published elsewhere 13. People with diabetes were identified if they self-reported 
(confirmed through medical record check) or had a baseline fasting glucose >7.8 mmol/L. 
One hundred and forty (8.3%) people had one or more baseline risk factors missing (six with 
missing systolic blood pressure value; 49 with missing total cholesterol and 134 with missing 
HDL cholesterol), and were excluded from the main analysis. Sensitivity analysis was 
conducted where we replaced the missing values with estimated values from multiple 
imputation by chained equations on five occasions and used standard statistical rules to 
produce reported results 14. ECG-LVH (required for the 1991 Framingham model) and 
hypertension treatment (required for the 2008 Framingham model) were not collected during 
WPHC screening. We presumed these values to be the average of the Framingham 
population and used hypothetical values in the sensitivity analysis. 
OUTCOMES 
CVD events were identified using the International Classification of Disease (ICD) diagnosis 
and procedure codes (versions 9 and10; see Appendix 1) for the following outcomes in 
hospitalisation and death records, 
 CHD (including myocardial infarction, angina pectoris and coronary insufficiency) 
 CHD death 
 Stroke 
 Congestive heart failure, and 
 Peripheral vascular disease as defined by Anderson et al. in the Framingham study 
2. 
The start date of follow-up was the screening date of the WPCH and the censor date was 
the date of first CVD event or death, whichever came first; or otherwise the date of last 
known admission. If neither admission nor death occurred during follow-up, the censor date 
was the 1st December 2014, which was the last known admission date of the study. 
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STATISTICAL ANALYSIS  
We used three models to predict 5-year and 10-year CVD risks in our study cohort. The first 
two were the original 1991 and 2008 Framingham models 2, 6. As only the 10-year baseline 
survival rate was reported in the 2008 Framingham model, this model predicted 10-year 
CVD risk only. The third model was a recalibrated 2008 Framingham equation, in which both 
the baseline 5-year and 10-year survival rates and mean values of the risk factors were 
estimated using the WPHC sample and coefficients on risk factors were obtained from the 
original 2008 Framingham model. 
In detail, the 2008 Framingham model (Cox equation): 𝑃 = 1 − 𝑆0(𝑡)
𝑒𝑥𝑝(∑𝛽𝑖𝑋𝑖−∑𝛽𝑖𝑀𝑖), where 
βi represents the regression coefficients, Xi represents an individual’s risk factors, Mi 
represents the means of the risk factors of the Framingham cohort, S0(t) represents the 
Framingham baseline CVD rate at year ten. To recalibrate this Framingham equation, we 
replaced the Framingham means of the risk factors (Mi) with the means in our own cohort, 
while the Framingham baseline CVD rate S0(t) was replaced with the cohort’s baseline 5-
year or 10-year CVD rate. The coefficients were kept the same as in the Framingham model 
(Table A, Appendix 2). 
Age- and sex-specific predicted 5-year (original 1991 and recalibrated 2008 models) and 10-
year (all three models) CVD risks for people aged between 30 and 74 years were calculated 
and compared with the observed CVD probabilities (estimated using the Kaplan-Meier 
method). The 95% confidence intervals of the differences between the predicted and 
observed probabilities were estimated using the bootstrap method with 1,000 bootstrapped 
replications. 
 
DISCRIMINATION  
Discrimination refers to the ability of a prediction model to correctly distinguish those who 
will develop an event from those who will not. We quantified this by calculating the Harrell’s 
C-statistic 15, which represents the probability of concordance amongst all pairs of subjects 
in which at least one had an event. Concordance refers to two subjects’ predicted 
probabilities of survival and survival times going in the same direction, e.g. the person who 
has higher predicted probability of survival also survives longer in reality. 
 
CALIBRATION  
Calibration describes how closely the predicted probabilities agree with observed outcomes. 
We used two χ2 statistics to evaluate calibration. The first method was proposed by 
D'Agostino and Nam 16, which compared the predicted and observed probabilities by deciles 
based on the predicted risk. Plots were constructed showing predicted and actual 
probabilities of CVD events in each decile. A χ2 statistic exceeding 20 was used to indicate 
a significant lack of calibration (P<0.01) 7. The second method used the χ2 statistics with 
cross-classified categories proposed by Cook 17, in which a reclassification table was built to 
divide participants into different risk categories based on predictions from both original and 
recalibrated Framingham models. The observed and predicted probabilities were compared 
for all cells with at least 20 individuals 17. 
To investigate the validity of the recalibrated model, the repeat data-splitting (cross 
validation) method was used for internal validation. The original sample was randomly 
divided into five samples; the recalibration was conducted on all sets of four of these 
samples, and the resulting five recalibrated models were used to estimate the risk in the 5th 
omitted sample (i.e. those individuals not used in the model development). The C-statistic 
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and Nam-D’Agostino chi-square were computed on the estimated results. This data-splitting 
procedure was repeated 200 times to obtain stable results. 
All statistical analyses were performed in Stata version 13.1(StataCorp LP, College Station, 
TX, USA). 
 
CVD RISK CHART 
A 5-year CVD risk chart for the Australian Indigenous population was generated based on 
the recalibrated 2008 Framingham model. To keep the chart simple and comparable to 
existing Australian CVD charts 18, we retained stratification by the total cholesterol: HDL 
ratio. This was achieved by fixing HDL at 1.2 mmol/L, the average level in this sample. We 
varied the HDL level by ±0.6 mmol/L (covering the maxim values of HDL in the study cohort) 
to test its effect on the predicted risk levels in a sensitivity analysis. 
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Results 
The study cohort consisted of 1,448 people from the WPHC cohort (see flowchart, Appendix 
3). Baseline risk factors of this cohort are provided in Table 1. Compared to the cohort used 
to estimate the 2008 Framingham model (6), our study cohort is slightly younger and has a 
higher proportion of smokers and diabetes patients at baseline. The 10-year baseline 
survival rates in the study cohort is much lower compared to the Framingham cohort (Table 
1). 
 
Table 1. Baseline risk factors and survival rates for people 30-75 years old in the 
Framingham (D’Agostino 2008) and WPHC Indigenous cohort 
 Framingham * WPHC cohort (30-75) † 
Risk factors 
Women 
n=4,522 
Men 
n=3,969 
Women 
n=748 
Men 
n=700 
Age, mean (SD), years 49.1 (11.1) 48.5 (10.8) 45.2 (11.6) 44.9 (11.0) 
Total-C, mean (SD), mmol/L 5.6 (1.1) 5.5 (1.0) 5.0 (1.0) 5.3 (1.1) 
HDL-C, mean (SD), mmol/L 1.5 (0.4) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 
Systolic BP, mean (SD), mm 
Hg 
125.8 
(20.0) 
129.7 (17.6) 
133.0 
(21.7) 
136.8 
(17.9) 
Smoking, n (%) 1548 (34.2) 1398 (35.2) 352 (47.1) 442 (63.1) 
Diabetes, n (%) 170 (3.8) 258 (6.5) 187 (25.0) 134 (19.1) 
Baseline 5-year survival rate NA NA 0.931 0.916 
Baseline 10-year survival rate 0.950 0.889 0.846 0.811 
 
WPHC, Well Person’s Health Check; SD, standard deviation; Total-C, total cholesterol; HDL-
C, high-density lipoprotein cholesterol; BP, blood pressure; NA, not applicable. 
* Adapted from data in D’Agostino 2008 
† The WPHC values were used for recalibration of the 2008 Framingham model 
 
 
The 1,448 people contributed 15,221 person-years of follow-up in total, with a mean and 
maximal follow-up time of 10.5 and 16.4 years, respectively. Three-hundred and sixty-nine 
(25.5%) people developed at least one CVD event during the follow-up. The 5- and 10-year 
probabilities of CVD events were 10.0% (95% CI: 8.5-11.7) and 18.7% (95% CI: 16.7-21.0), 
respectively (Table 2). 
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Table 2. 5-year and 10-year probability of CVD events in the WPHC indigenous sample, 
observed and predicted probabilities using three different Framingham models 
 
Sample 
size, n 
Observed 
probability, 
% (95% CI) 
Predicted probability, % (95% CI) 
Framingham 
1991 
Framingham 
2008 
Recalibrated 
Framingham 
2008 
5-year risk 
Total 1448 10.0 (8.5-11.7) 6.8 (6.4-7.2) NA* 10.4 (9.9-10.9) 
Gender 
Female 748 9.2 (7.3-11.6) 5.7 (5.2-6.2) NA* 9.6 (8.9-10.3) 
Male 
700 10.8 (8.7-13.4) 8.0 (7.4-8.5) NA* 
11.3 (10.5-
12.1) 
Age group 
30-34 301 3.5 (1.9-6.5) 1.3 (1.2-1.5) NA* 2.8 (2.6-3.1) 
35-44 486 3.9 (2.5-6.2) 3.8 (3.4-4.1) NA* 6.2 (5.8-6.6) 
45-54 354 
13.5 (10.3-
17.6) 
8.0 (7.5-8.6) NA* 
11.9 (11.1-
12.7) 
55-74 307 
21.7 (17.4-
26.8) 
15.5 (14.5-
16.5) 
NA* 
22.7 (21.2-
24.2) 
10-year risk 
Total 1448 
18.7 (16.7-
21.0) 
14.2 (13.5-
14.8) 
12.0 (11.4-
12.6) 
21.2 (20.3-
22.1) 
Gender 
Female 748 
17.3 (14.7-
20.5) 
12.2 (11.3-
13.0) 
8.9 (8.2-9.5) 
19.6 (18.3-
20.8) 
Male 700 
20.2 (17.2-
23.6) 
16.3 (15.3-
17.3) 
15.4 (14.3-
16.4) 
22.9 (21.5-
24.3) 
Age group 
30-34 301 8.1 (5.4-12.2) 3.5 (3.2-3.9) 3.3 (3.0-3.6) 6.5 (6.0-7.0) 
35-44 486 12.0 (9.2-15.5) 8.9 (8.3-9.5) 7.3 (6.8-7.8) 
13.7 (12.8-
14.5) 
45-54 354 
24.5 (20.1-
29.6) 
17.2 (16.2-
18.2) 
14.1 (13.1-
15.1) 
25.0 (23.6-
26.5) 
55-74 307 
32.8 (27.6-
38.7) 
29.5 (28.0-
31.0) 
25.6 (23.9-
27.4) 
43.1 (40.9-
45.3) 
CVD, cardiovascular disease; WPHC, Well Person’s Health Check; NA, not applicable 
* The baseline 5-year survival rate was not reported in the D’Agostino 2008 study. Therefore, 
we were unable to calculate 5-year risk using the original Framingham 2008 model. 
 
The overall predicted 5-year CVD risk using the 1991 Framingham model was 6.8% (95% 
CI: 6.4-7.2). The predicted 10-year risk was 14.2% (95% CI: 13.5-14.8) and 12.0% (95% CI: 
11.4-12.6) using the 1991 and 2008 Framingham models, respectively. All predictions 
significantly underestimated the observed CVD probabilities in the WPHC cohort by around 
a third, with differences being 3.2% (95% CI: 1.9-4.5) for 5-year risk and 4.5% (95% CI: 2.9-
6.3) to 6.7% (95% CI: 5.0-8.5) for 10-year risk. Sensitivity analyses which estimated 
predicted risk by adjusting the prevalence of ECG-LVH or hypertension produced similar 
results and were reported in supplementary materials. 
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After baseline risk recalibration, 5-year total and age- sex-specific predicted risks were 
similar to the observed results (Table 2). The predicted 10-year probability of CVD events 
using the recalibrated model was higher than the observed risk, mainly because of 
overestimation in the 55-74 year age group (Table 2). Compared to the predictions from the 
original 1991 Framingham model, after recalibration 165/1096 people in the low 5-year CVD 
risk (<10%) category and 146/186 people in the moderate 5-year CVD risk (10%-15%) 
category moved to a higher risk category; the predicted number of people with high 5-year 
CVD risk (>15%) almost doubled from 166 to 322 in the cohort (P<0.001). The probabilities 
of CVD events using the imputed data was similar and reported in supplementary materials. 
 
Table 3. Performance of the original and recalibrated Framingham models in predicting 5-
year and 10-year CVD events 
  Original Framingham 
Recalibrated  
Framingham 
2008   1991 2008 
5-year risk 
Discrimination     
C 0.671 NA † 0.674 
95 % CI of C (0.643-0.699) NA † (0.646-0.702) 
Calibration 
Nam-D’Agostino χ2 (9) 85.44 NA † 18.48 
P value for Nam-D’Agostino 
χ2  <0.001*** NA † 0.03* 
Cook χ2 (6) 43.84 NA † 11.82 
P value for Cook χ2 <0.001*** NA † 0.07* 
10-year risk 
Discrimination     
C 0.671 0.668 0.674 
95 % CI of C (0.643-0.699) (0.640-0.696) (0.646-0.702) 
Calibration  
Nam-D’Agostino χ2 (9) 82.56  134.67  51.09  
P value for Nam-D’Agostino 
χ2  <0.001*** <0.001*** <0.001*** 
Cook χ2 (6) 65.91 116.13 34.65 
P value for Cook χ2 <0.001*** <0.001*** <0.001*** 
 
CVD, cardiovascular disease; C, C-statistics; CI, confidence interval; NA, not applicable. 
† The baseline 5-year survival rate was not reported in the D’Agostino 2008 study. Therefore, 
we were unable to calculate 5-year risk using the original Framingham 2008 model. 
* not statistically significant 
*** highly statistically significant using a p-value cut-point of 0.05 
 
 
Table 3 contains the C-statistics and χ2 estimates for different models. The C-statistics were 
between 0.668 and 0.674, with no significant differences. We found a significant lack of 
calibration (P<0.001) for the original (5- and 10-year) and recalibrated (10-year) 
Framingham risk estimations. 
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Figure 1.  Calibration by decile for CVD risk of the original and recalibrated 2008 Framingham 
model. Horizontal-axes refer to decile of predicted risk based on the 2008 Framingham CVD 
model; vertical-axes refer to observed and model-based predicted probabilities of CVD event. 
 
The recalibrated 5-year risk prediction showed improvement on calibration (Nam-D’Agostino 
χ2=18.48, p=0.03, Cook χ2 =11.82, p=0.07). Figure 1 compares predicted risks using the 
2008 Framingham model and actual risks of CVD events for each decile of predicted risk. 
The original model (Figure 1A) shows poor calibration between estimated and observed risk 
in all deciles, except for the last decile. This was greatly improved after recalibration (Figure 
1B); however, for the recalibrated 10-year risk large differences are still evident between the 
estimated and observed risks in the last decile. The performance of the recalibrated model 
on 5-year risk prediction did not change after internal validation, with a C-statistic of 0.678 
(95% CI: 0.616-0.728) and Nam-D’Agostino χ2 of 14.4 (95% CI: 10.0-20.9). 
Based on the recalibrated 2008 Framingham model, a 5-year absolute CVD risk chart was 
built for the Australian Indigenous population (Figure 2). Predictions for people aged 
between 30 and 34 years were included because of the high CVD risk levels for certain 
populations in this age range (e.g. smokers with diabetes). A sensitivity analysis (reported in 
Appendix 4) showed that varying HDL levels by ±0.6 mmol/L produced only a small change 
of risk scores that would have a minimal impact on the classification of standard risk charts. 
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Figure 2 Five-year cardiovascular risk charts based on the recalibrated Framingham model. 
*This chart is based on 2008 Framingham model that has been recalibrated using 
information on Aboriginal and Torres Strait Islander participants from the Well Persons Health 
Check study which recruited people from 26 remote communities from Far North 
Queensland. It has not been validated for use in other Indigenous populations. 
†For people under treatment for high blood pressure, 5% should be added to the risk on the 
chart. 
[The Well Person's Health Check: a population screening program in indigenous 
communities in north Queensland13] 
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Discussion 
The 1991 and 2008 Framingham CVD models substantially underestimated the absolute 
CVD risk in the Australian Indigenous cohort used in our study. Both models showed a lack 
of calibration to the observed CVD probabilities. Using the baseline risk from our study 
population we recalibrated the 5-year CVD risk to a level considered acceptable by the 
developers of the Framingham model 7. The recalibrated equation was used to calculate the 
first CVD risk chart based on empirical validation using long-term follow-up data from an 
Indigenous Australian population. 
The high CVD risk among Indigenous people presented in this study is not unique in 
Australia. The Strong Heart Study found that CHD rates in American Indians exceed rates in 
other US population and may more often be fatal 19. A study in Canada found that Aboriginal 
people had a significantly higher frequency of CVD compared with Europeans (18.5% vs 
7.6%) 20. Although a variety of CVD risk models are available, few are based or calibrated 
using the observed risk in Indigenous populations. In the Strong Heart Study, both 
recalibration on the Framingham model and development of specific risk equation for the 
American Indians have been conducted to help better stratify the CHD risks in this 
population 7, 21. As far as we are aware, there is no similar study for the Indigenous people in 
Australia. So, instead of trying more CVD risk models which were built based on other 
populations, we feel it is important to generate/recalibrate a prediction tool based on 
Indigenous Australian data. We hope this study represents a first step to producing a more 
accurate estimate on CVD risk for Indigenous people in Australia. 
 
IMPLICATIONS  
There is an important practical application of this research, as a previous study on CVD risk 
identification and management in Indigenous Australians showed that more than half of this 
population were not screened for CVD as recommended in national guidelines for 
cardiovascular risk management 19. Current guidelines for remote health services in 
Indigenous communities use a CVD Risk Assessment tool which is an adaptation of the 
general Australian CVD charts based on the 1991 Framingham model 18, with a 5% upwards 
adjustment and additional estimates for a younger cohort aged 20-44 23. In this study we 
provide a risk chart derived from the recalibrated Framingham model based on the actual 
risk observed in a remote Indigenous population and so provides evidence that enables 
prediction of risk to be refined. 
The more accurate calculation of CVD risk will enable better identification for Indigenous 
Australians in primary prevention. However, the assessment of CVD risk is just one 
component of a wide range of strategies to improve Indigenous health and thereby achieve 
the Council of Australian Governments’ target on Closing the Gap in life expectancy 24. To 
tackle the large numbers of high CVD risk patients more resources are required. This will 
need co-ordination with a range of primary care and allied health practitioners. Key to this 
will be the development of early risk intervention teams as well as broader community 
strategies such as improving infrastructure to promote healthy behaviours in Indigenous 
communities. 
 
FUTURE STUDIES  
After baseline calibration, there was no significant difference between the predicted and the 
observed 5-year CVD risks. However, overestimation occurred when using the recalibrated 
10-year prediction model, mainly because of overestimation in the older age group. Hence 
we produced 5-year absolute CVD risk charts only. Unlike most of the guidelines in other 
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countries that dictated therapeutic intervention strategies based on 10-year CVD risk 
predictions 25, the current Australian guidelines for primary prevention of cardiovascular 
disease made the suggestions based on 5-year CVD risk estimations. So, we hope the 5-
year risk charts produced in this study can provide reference to identify Indigenous 
Australian under high CVD risks. 
However, future study should work on generating more accurate predictions for 10-year 
CVD risk as well, so clinical decisions can be made based on both short term and long-term 
risk estimations. 
According to the data released by the Australian Bureau of Statistics, it was estimated that 
in 2011 there were 669,900 Indigenous people in Australia, accounting for 3% of the total 
Australian population; the largest population of Indigenous Australians lived in New South 
Wales (31.1%) and Queensland (28.2%); 34.8% of all Indigenous Australians lived in major 
cities of Australia, 43.8% people lived in inner or outer regional Australia and 21.4% lived in 
remote Australia 26. Based on the Australian Aboriginal and Torres Strait Islander Health 
Survey in 2013, there was no significant difference on various health conditions and risk 
factors for Indigenous people across different states/territories in Australia 27. While the 
study used a cohort from North Queensland, our results are consistent with a previous study 
that used an Indigenous cohort from remote regions of central Australia that also showed 
the Framingham model underestimated CHD rates 12. Currently there is no corresponding 
study available on the CVD risk of Indigenous Australians in non-remote areas and so 
further external validation of our recalibrated model is required to determine the clinical utility 
of these risk charts in other Indigenous populations. 
After adjustment of the baseline risk of the Framingham model in this study, calibration of 
the model largely improved but discrimination had no significant change. Previous studies 
have showed that other risk factors such as urinary albumin creatinine ratio and waist 
circumference and triglycerides also contributed to the development of CVD in a population 
with a high prevalence of diabetes 21, 28-29. Another possible risk factor is rheumatic heart 
disease which can increase the risk for certain types of CVD (heart failure and stroke) and 
has high prevalence and mortality rate among Australian Indigenous people 30, 31. This 
suggests that further recalibration which includes other predictors of CVD risk or the 
development of a new model specifically for the Australian Indigenous population which 
incorporates these risk factors should be a research priority. It would also be interesting to 
look at the population attributed risk for each of the tradition and new risk factors in the 
Indigenous population, which would provide evidence to promote more targeted strategies 
to reduce CVD risks. 
 
STRENGTHS AND L IMITATIONS  
Strengths of the present study include the use of relatively large baseline sample, long 
follow-up and objective measures (rather than self-reported) of baseline risk factors. There 
are also some limitations of our study. The participants of this study were from remote 
Indigenous communities in Far North Queensland who volunteered to participate in a 
population screening program. The mode of recruitment may have influenced the 
representativeness of the sample, which would impact on generalisability if other factors not 
contained in the Framingham models influences risk (e.g. body mass index) and differs 
between the sample and the population. External validation on our recalibrated Framingham 
model should be conducted in future studies involving other Indigenous populations (e.g. 
Indigenous Australians living in urban areas). Second, parametric uncertainty was not 
considered in this study when comparing observed and predicted CVD probabilities, as no 
variance-covariance matrices were reported for the original Framingham CVD models 32. 
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Conclusion 
In conclusion, we found that both the 1991 and 2008 Framingham model underestimated 
the CVD risk in the Australian Indigenous population by about one third on average. A 
recalibrated equation was used to calculate the first risk chart based on empirical validation 
using long-term follow-up data from remote Indigenous communities in Far North 
Queensland. 
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Appendix 1:  ICD and procedure codes used to identify 
CVD events 
 
 
 
 CHD, including  
MI 
angina pectoris                         
coronary insufficiency  
CHD death           → death of cause          
 
 Stroke    → 
 
 
 
 Congestive heart failure             
→  
 
 
 Peripheral vascular disease       
→  
 
 
 
 
Procedure codes for CVD    
→ 
 
 
 
 
 
icd9: 4100-4149 (except 4110)    
icd10: I200-I259 (except I241) 
 
icd9: 4330-4359, 4370  
icd10: G450-G468 (except G454) 
            I600-I672 (except I620-I629, I671) 
 
 
icd9: 4280-4289 
icd10: I500-I509 
            I110, I130, I132 
 
icd9: 4400-4417 (except 4412, 4414, 4416) 
          4439, 4440-4449 
icd10: I700-I718 (except I712, I714, I716) 
            I739-I749 
 
 
icd9: 3600-3699 
icd10: 3270000-3271801, 3273000-3275701, 3276300-3276303,  
3276305- 3276314, 3276316-3276319, 3305000-3305500, 3307500-
3310000, 3311200 -3313000, 3315100-3316300, 3317800-3355400, 
3530306-3530501, 3530906 -3531501, 3845619, 3849700-3850900, 
3863700, 9020100-9020103 
9022900-9023000 
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Appendix 2:  Recalibration of the 2008 Framingham CVD 
model 
 
2008 Framingham COX equation: 
𝑃 = 1 − 𝑆0(𝑡)
𝑒𝑥𝑝(∑𝛽𝑖𝑋𝑖−∑𝛽𝑖𝑀𝑖) 
, where βi represents the regression coefficients, xi represents an individual’s risk factors, Mi 
represents the means of the risk factors of the Framingham cohort. S0(t) is the Framingham 
baseline CVD rate at year 10. 
To recalibrate this Framingham equation, we replaced the Framingham means of the risk 
factors (Mi) by the means in our own cohort, while the Framingham baseline CVD rate S0(t) 
was replace by the cohort’s own baseline 5-year CVD rate. The coefficients were kept the 
same as in the Framingham equation (table A). 
 
Table A. Regression coefficients in the Framingham study 
 Women Men 
Log of age 2.32888 3.06117 
Log of total cholesterol 1.20904 1.12370 
Log of HDL -0.70833 -0.93263 
Log of SBP if not treated* 2.76157 1.93303 
Log of SBP if treated 2.82263 1.99881 
Smoking 0.52873 0.65451 
Diabetes 0.69154 0.57367 
*High blood pressure treated rate in the Framingham cohort is 0.1176 and 0.1013 for women 
and men respectively 
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Appendix 3:  Flow chart of the sample selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3508 people  
in the WPHC 
study 
2372 people  
-560 none indigenous; 
-197 younger than 15 years old; 
-379 not consent to access to 
medical records 
1494 people  
30 to 74 years old  
878 people  
15 to 29 years old 
865 people 1368 people  
-126 people with 
previous CVD 
events 
-13 people with 
previous CVD 
events 
Used to validate and 
recalibrate the 
Framingham models 
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Appendix 3:  Recalibrated risk scores under different HDL 
levels – Sensitivity analysis 
 
 
 
Using the recalibrated 2008 Framingham CVD model, the 5-year CVD risk of an “average” 
male or female (with risk factors equal to those reported in Table 1, total cholesterol five 
times of HDL level) can be found in the following Table B, 
 
Table B. Recalibrated risk score of an average person under different HDL levels 
HDL, 
mg/dL 
Risk score for 
female 
Difference from 
HDL of 45 mg/dL, 
female 
Risk score for 
male 
Difference from 
HDL of 45 mg/dL, 
male 
20 6.1% -2.9% 7.4% -1.2% 
25 6.8% -2.2% 7.8% -0.9% 
30 7.4% -1.6% 8.0% -0.6% 
35 8.0% -1.0% 8.3% -0.4% 
40 8.5% -0.5% 8.5% -0.2% 
45 9.0% 0.0% 8.6% 0.0% 
50 9.5% 0.5% 8.8% 0.2% 
55 9.9% 0.9% 9.0% 0.3% 
60 10.4% 1.3% 9.1% 0.5% 
65 10.8% 1.7% 9.2% 0.6% 
70 11.1% 2.1% 9.4% 0.7% 
 
We used the fixed HDL level of 45 mg/dL to build the Indigenous CVD chart. By varying the 
HDL level of ± 25 mg/dL, the change in risk score range from -2.9% to 2.1%, and -1.2% to 
0.7% for female and male respectively, which would have a minimal impact on the 
classification for the chart. 
 
 
